We hypothesize that the assessment of FL-SMN percentage in blood cells of SMA patients treated by Nusinersen will not provide meaningful data because the drug is administered intrathecally, and whole-body distribution was not demonstrated [6]. This evidence concerns the gene SMN1 and proximal spinal muscular atrophy.